Compare AU
Compare VLC vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Vanguard MSCI Australian Large Companies Index ETF (VLC) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
VLC | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 52 | 78 |
Median incremental investment | $1,000.00 | $640.11 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,062.06 | $1,274.70 |
Average age group | > 35 | > 35 |
Key Summary
VLC | CURE | |
|---|---|---|
Strategy | VLC.AX was created on 2011-05-23 by Vanguard. The fund's investment portfolio concentrates primarily on large cap equity. To closely track the MSCI Australian Shares Large Cap Index, the Fund will hold all of the securities in the index. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 27.78m in AUM and 125 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | BHP Group Ltd. (17.50 %) Commonwealth Bank of Australia (13.40 %) CSL Ltd. (9.73 %) | Natera Inc (2.73 %) Alnylam Pharmaceuticals Inc (2.65 %) Vertex Pharmaceuticals Inc (2.64 %) |
Top 3 industries | Financials (36.62 %) Materials (25.30 %) Health Care (9.73 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | Australia (100.00 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.2 % | 0.45 % |
Key Summary
VLC | CURE | |
|---|---|---|
Issuer | Vanguard | Global X |
Tracking index | MSCI Australian Shares Large Cap Index - AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.2 % | 0.45 % |
Price | $79.31 | $42.49 |
Size | N/A | $28.994 million |
10Y return | 18.64 % | N/A |
Annual distribution yield (5Y) | 6.92 % | 4.24 % |
Market | ASX | ASX |
First listed date | 26/05/2011 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
VLC | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 52 | 78 |
Median incremental investment | $1,000.00 | $640.11 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,062.06 | $1,274.70 |
Average age group | > 35 | > 35 |
Pros and Cons
VLC | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
VLC | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |